Progenics Makes Further Job Cuts

Progenics Pharmaceuticals are laying off more than a quarter of their workforce after failing to gain extended approval for their constipation drug, Relistor. The organisation noted that they are ending several early-stage research projects in order to concentrate on their cancer programmes, in particular a Phase II study of PSMA ADC, a human monoclonal antibody-drug

Continue Reading

J&J Resolves ADHD Lawsuit with Impax Labs and Teva

Johnson & Johnson (J&J) have established a new deal to settle a patent disagreement regarding their attention-deficit hyperactivity disorder (ADHD) drug, Concerta. Impax Laboratories and partner Teva Pharmaceutical Industries launched a lawsuit against Johnson & Johnson’s Janssen Pharmaceuticals and Alza Corp units.  Impax Laboratories announced on Friday that the lawsuit has now been settled after

Continue Reading

Agennix Cuts 55% of Jobs

After the failure of their experimental lung cancer drug, talactoferrin, in a late-stage clinical trial, Germany’s Agennix announced on Friday that they are reducing their workforce by roughly 55%. The restructuring plan will result in 37 jobs being lost and the firm’s Houston, USA site being closed down.  Around 30 staff will remain in the

Continue Reading

Competition Warning for Eight NHS Trusts

Eight NHS hospital trusts have provided guarantees to the Office of Fair Trading (OFT) that they will stop exchanging commercially-sensitive information about their Private Patient Unit (PPU) prices, and ensure that they conform to competition law. The Office of Fair Trading confronted members of the Southern Region Private Healthcare Association (SPHA) earlier this year, after

Continue Reading

AstraZeneca Teams With Regulus’ MicroRNA Therapeutics

AstraZeneca has announced that they have entered into a strategic partnership with US biopharmaceutical group Regulus Therapeutics to discover, develop, and commercialise microRNA therapeutics. The Anglo-Swedish drug giant has agreed to pay $28 million, which includes an equity investment and an upfront fee, so they can exclusively work with Regulus on the development of three

Continue Reading

Elan Separates Discovery Activities into Neotope

Elan today has announced that they have decided to spin off of their discovery science and Neotope Biosciences divisions into a separate business entity “to create two independent, highly focused, public companies.” After the separation, Elan will hold three key assets: the multiple sclerosis blockbuster Tysabri and its other potential indications; ELND005, a Phase II/Phase

Continue Reading

UK Branded Drug Pricing Arrangements from 2014

The UK department of health and the ABPI (Association of the British Pharmaceutical Industry) have set the groundwork for discussions over the new pricing structure for medicines in the UK, which will come into force in 2014 after the current Pharmaceutical Price Regulation Scheme (PPRS) scheme finishes. In a joint statement released Friday they confirmed

Continue Reading

Teva Profits Increased by US Generic Sales

Teva Pharmaceutical Industries announced solid financials for the second quarter of 2012, improved by sales of their multiple sclerosis drug Copaxone, sturdy generics growth in the US and the contribution of Cephalon’s products. Net income increased by 50% to $863 billion, while sales grew 19% to $4.99 billion.  Turnover climbed by 28% in America to

Continue Reading